Physician profile
Shahida Bashir
NPI 1508074063
$459.36
in general payments reported to CMS, 2019-2025
8 companies · $17.24 in 2025
The $17.24 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.28 · 2020: $155 · 2021: $113 · 2022: $56.42 · 2023: $40.24 · 2025: $17.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $210.75 | 2019-2023 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $73.46 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.86 | 2020 | |
| Advanced Respiratory, INC | $38.99 | 2020 | |
| Abbvie INC. | $24.62 | 2021 | |
| Merck Sharp & Dohme LLC | $21.39 | 2023 | |
| Glaxosmithkline, LLC. | $17.24 | 2025 | Trelegy Ellipta |
| Eisai INC. | $16.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahida Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.